Fideuram Asset Management Ireland dac Makes New $681,000 Investment in IDEXX Laboratories, Inc. $IDXX

Fideuram Asset Management Ireland dac acquired a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 1,007 shares of the company’s stock, valued at approximately $681,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. EverSource Wealth Advisors LLC boosted its position in IDEXX Laboratories by 2.5% during the third quarter. EverSource Wealth Advisors LLC now owns 621 shares of the company’s stock worth $397,000 after purchasing an additional 15 shares during the period. Harbour Investments Inc. boosted its position in IDEXX Laboratories by 13.3% during the fourth quarter. Harbour Investments Inc. now owns 136 shares of the company’s stock worth $92,000 after purchasing an additional 16 shares during the period. CWA Asset Management Group LLC boosted its position in shares of IDEXX Laboratories by 3.5% in the fourth quarter. CWA Asset Management Group LLC now owns 509 shares of the company’s stock valued at $344,000 after acquiring an additional 17 shares during the period. Stratos Wealth Partners LTD. boosted its position in shares of IDEXX Laboratories by 1.7% in the third quarter. Stratos Wealth Partners LTD. now owns 1,069 shares of the company’s stock valued at $683,000 after acquiring an additional 18 shares during the period. Finally, Cary Street Partners Investment Advisory LLC grew its stake in shares of IDEXX Laboratories by 11.5% in the third quarter. Cary Street Partners Investment Advisory LLC now owns 174 shares of the company’s stock valued at $111,000 after acquiring an additional 18 shares in the last quarter. 87.84% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently commented on IDXX. BTIG Research decreased their price target on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating on the stock in a research note on Tuesday, February 3rd. UBS Group decreased their price target on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 28th. Weiss Ratings downgraded shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 11th. Piper Sandler decreased their price target on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a research note on Monday, February 9th. Finally, Barclays decreased their price target on shares of IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a research note on Thursday, February 5th. Seven investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat, IDEXX Laboratories presently has an average rating of “Moderate Buy” and a consensus price target of $751.00.

IDEXX Laboratories Trading Down 0.8%

IDXX opened at $563.53 on Friday. IDEXX Laboratories, Inc. has a twelve month low of $504.56 and a twelve month high of $769.98. The company has a 50-day simple moving average of $564.58 and a 200 day simple moving average of $637.19. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19. The stock has a market capitalization of $44.45 billion, a price-to-earnings ratio of 41.50, a P/E/G ratio of 3.27 and a beta of 1.58.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, topping the consensus estimate of $3.41 by $0.06. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The business had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.12 billion. During the same quarter in the prior year, the business posted $2.91 earnings per share. IDEXX Laboratories’s revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Analysts predict that IDEXX Laboratories, Inc. will post 14.68 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Nimrata Hunt sold 1,758 shares of the company’s stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $634.57, for a total transaction of $1,115,574.06. Following the completion of the sale, the executive vice president owned 18,141 shares of the company’s stock, valued at $11,511,734.37. This represents a 8.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 0.79% of the stock is owned by corporate insiders.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.